User:Mr. Ibrahem/Terlipressin
Clinical data | |
---|---|
Trade names | Teripress, Glypressin, Terlivaz, others |
Other names | Terlipressin acetate, triglycyl lysine vasopressin |
AHFS/Drugs.com | Monograph |
Routes of administration | IV |
Drug class | Vasopressin analog[1] |
Pharmacokinetic data | |
Protein binding | ~30% |
Identifiers | |
| |
Chemical and physical data | |
Formula | C52H74N16O15S2 |
Molar mass | 1227.38 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Terlipressin, sold under the brand names Teripress among others, is a medication used to treat bleeding esophageal varices and kidney problems in hepatorenal syndrome.[2][3] In these conditions it decreases the risk of death.[4] It is given by injection into a vein.[3]
Common side effects include abdominal pain, nausea, respiratory failure, and diarrhea.[3] Other side effects may include mesenteric ischemia and heart ischemia.[3] Use during pregnancy may harm the baby.[3] It is a vasopressin receptor activator.[3]
Terlipressin has been in medical use in various parts of the world since 1975.[4] It was approved for medical use in the United States in 2022.[3] In the United Kingdom it costs the NHS about £18 for 1 mg vial as of 2021.[2]
References[edit]
- ^ Srivastava, Ved (22 June 2017). Peptide-based Drug Discovery: Challenges and New Therapeutics. Royal Society of Chemistry. p. 187. ISBN 978-1-78801-171-6. Archived from the original on 14 December 2022. Retrieved 14 December 2022.
- ^ a b c BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 98. ISBN 978-0857114105.
- ^ a b c d e f g h i "DailyMed - TERLIVAZ- terlipressin injection, powder, lyophilized, for solution". dailymed.nlm.nih.gov. Archived from the original on 28 September 2022. Retrieved 12 December 2022.
- ^ a b Kulkarni, Anand V.; Arab, Juan Pablo; Premkumar, Madhumita; Benítez, Carlos; Tirumalige Ravikumar, Sowmya; Kumar, Pramod; Sharma, Mithun; Reddy, Duvvuru Nageshwar; Simonetto, Douglas A.; Rao, Padaki Nagaraja (December 2020). "Terlipressin has stood the test of time: Clinical overview in 2020 and future perspectives". Liver International. 40 (12): 2888–2905. doi:10.1111/liv.14703.